HIV-1	human immunodeficiency virus type one
IN	integrase
PR	protease
RT	reverse transcriptase
WT	wild-type
3′-P	3′-processing
ST	strand transfer
PrEP	pre-exposure prophylaxis
ART	antiretroviral therapy
INSTIs	integrase strand transfer inhibitors
NRTIs	nucleoside reverse transcription inhibitors
NNRTIs	nonnucleoside RT inhibitors
RAL	raltegravir
EVG	elvitegravir
DTG	dolutegravir
BIC	bictegravir
PFV	prototype foamy virus
SIV	simian immunodeficiency virus
HIV-2	human immunodeficiency virus type two
rcm	red-capped mangabey
HCV	hepatitis C virus
DKAs	2,4-diketobutanoic acids
EFV	efavirenz
FTC	emtricitabine
TDF	tenofovir disoproxil fumarate
RPV	rilpivirine
FC	fold change
SAR	structure activity relationship
CTD	C-terminal domain
LATTE	long-acting antiretroviral treatment enabling
FLAIR	the first long-acting injectable regimen trial
ATLAS	the antiretroviral therapy as long-acting suppression trial